Evonik keeps full-year guidance after Q3 profit beat despite 22% drop

Evonik Industries reported a 22% year-over-year decline in Q3 adjusted EBITDA to 448 million euros, slightly exceeding analyst expectations of 440 million euros, as weak demand persisted and September's anticipated recovery failed to materialize. Despite this, the German chemicals producer reaffirmed its full-year 2025 guidance for EBITDA of approximately 1.9 billion euros and revenue of 14-15 billion euros, aligning with market consensus, though it notably withheld a detailed Q4 outlook, signaling management's confidence in long-term targets despite current market headwinds and significant Q3 declines in net income and revenue.

Analysis

Evonik Industries reported a 22% year-over-year decline in Q3 adjusted EBITDA to 448 million euros, reflecting persistent weak demand and a difficult market environment. Despite this significant drop, the result slightly surpassed analyst expectations of 440 million euros, according to Vara Research. Revenue also fell 12% to 3.39 billion euros, with adjusted net income decreasing from 271 million euros to 128 million euros.

Despite the challenging Q3, Evonik maintained its full-year 2025 guidance, reaffirming EBITDA of approximately 1.9 billion euros and revenue between 14 billion and 15 billion euros, aligning with market consensus. CEO Christian Kullmann acknowledged the short-term pain from the failed September recovery but emphasized the company remains on its long-term course. The interim CFO, Claus Rettig, stated that revised targets for the year are achievable, focusing on long-term growth and cost-cutting programs.

Notably, Evonik broke from its usual practice by not providing a detailed Q4 outlook, which introduces some near-term uncertainty. However, the maintained full-year guidance implies a Q4 EBITDA of 383 million euros, slightly above the Vara Research consensus of 370 million euros. This suggests management anticipates a stronger Q4 relative to analyst expectations to meet its annual targets, despite the lack of explicit forward-looking statements for the quarter.

Key Decisions for Investors

• Monitor Q4 performance closely for signs of recovery, especially given the implied EBITDA target and the absence of explicit Q4 guidance.
• Evaluate the company's ability to execute on its long-term growth and cost-cutting programs, as management's confidence in full-year guidance hinges on these initiatives.
• Assess the broader market environment for chemical producers, as persistent weak demand remains a key headwind despite Evonik's slight beat on Q3 EBITDA expectations.